Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation (EAU2)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Recent studies show that EET and 20-HETE have important biological effects, particularly in the vascular system. The investigators studied the effect of eicosanoids on the gravid rat uterus. The results suggest that 20-HETE had an tocolytics effect on gravid uterus. In the previous study, we demonstrated that the enzymes of the pathway of EET were present in human uterine tissues. Moreover, the addition of an inhibitor of degradation of EET had an tocolytic effect on the human myometrium, as the exogenous addition of 8.9, 14,15-EET and 20-HETE.
Objectives:
Primary objective: To compare the balance of different metabolic pathways of arachidonic acid (AA) of the pregnant human myometrium in pathological situations (preterm labor, uterine atony, prolonged pregnancy).
Specific objectives: i) To study the effect of derived from the AA on in vitro contractile activity of normal and pathological uterine tissues, and ii) detect and quantify the different sub-products of metabolism of AA in the uterine tissues (myometrium, fetal membranes and placenta).
The management of uterine contraction is in the heart of modern obstetrics year, yet the progress made in other specialties, based on the study of smooth muscle have not yet been transposed in obstetrics. A better understanding of systems for regulating the contraction is important in terms of 1) new physiological knowledge, but it could also be the source of 2) modification of strategies to take care of premature delivery (new Tocolytic), or 3) improving the efficiency of uterine muscle during delivery or 4) for treatment of patients with prolonged pregnancy.
| Condition |
|---|
|
Obstetric Labor Complications Prolonged Pregnancy |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation. |
- effect of eicosanoids on contractile activity of myometrium of pregnant women with pathological situations [ Time Frame: during c-section ] [ Designated as safety issue: No ]
- effect of enzymatic inhibitors on contractile activity of myometrium from pregnant women with pathological situations [ Time Frame: during c-section ] [ Designated as safety issue: No ]
- detection of enzymes from the different pathways [ Time Frame: after c-section ] [ Designated as safety issue: No ]
- quantification of eicosanoids in different tissues [ Time Frame: after c-section ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
uterus biopsy
| Estimated Enrollment: | 130 |
| Study Start Date: | May 2009 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
EAU2
Women who will have a c-section at the CHUS
|
Detailed Description:
It is a clinical study with a slope fundamental aims to examine the metabolic pathways of AA of human myometrium and their functional roles according to their clinical profile divided into three contractile pathological situations - threat of premature delivery, dynamic dystocia, prolonged pregnancy - and two groups of patients at term: a group before work and group work.
The sampling method. After birth, a biopsy will be perform from the lower segment of the uterus. After caesarean sections of membrane and placenta are collected.
The substances studied during isometric tension tests are part of the three degradation pathways of the AA.
- new eicosanoids in cumulative dose (8,9-EET, 11,12-EET, 14,15-EET, 20-HETE), and in combination
- enzyme inhibitors of the eicosanoids pathway (AUDA, MS-PPOH, DDMS), and the COX and LOX pathways (indomethacin), alone or in combination.
Eligibility| Ages Eligible for Study: | 18 Years to 40 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
women who will have a c-section at the CHUS
Inclusion Criteria:
- all women who will have a c-section
Exclusion Criteria:
- induction of labor,
- child with malformation,
- birth weight less than 2500 grams or greater than 4500g
Contacts and Locations| Contact: Stéphanie Corriveau, BSc | 819 346-1110 ext 13875 | stephanie.corriveau@usherbrooke.ca |
| Contact: Simon Blouin, PhD | 819 346-1110 ext 13877 | syblouin.chus@ssss.gouv.qc.ca |
| Canada, Quebec | |
| Centre hospitalier de l'Université de Sherbrooke | Recruiting |
| Sherbrooke, Quebec, Canada, J1H 5N4 | |
| Principal Investigator: | Jean-Charles Pasquier, MD, PhD | Centre hospitalier de l'Université de Sherbrooke |
| Principal Investigator: | Rousseau Éric, PhD | Universitaire de Sherbrooke |
More Information
No publications provided by Universitaire de Sherbrooke
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Jean-Charles Pasquier, MD, PhD, Dr, Universitaire de Sherbrooke |
| ClinicalTrials.gov Identifier: | NCT00939744 History of Changes |
| Other Study ID Numbers: | 09-040 |
| Study First Received: | July 14, 2009 |
| Last Updated: | January 15, 2013 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Universitaire de Sherbrooke:
|
contractile activity eicosanoids pregnant women obstetrics complications |
Additional relevant MeSH terms:
|
Obstetric Labor Complications Pregnancy, Prolonged Pregnancy Complications |
ClinicalTrials.gov processed this record on May 21, 2013